
Yaron Pereg, KAHR CEO
An Israeli biotech is looking to make its name in the jam-packed CD47 space. Is bifunctionality the answer?
Jerusalem’s KAHR Medical had been working on fusion proteins for autoimmune disorders for about 10 years, before “issues in development” spurred then-new CEO Yaron Pereg …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.